文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

急性心肌梗死所致体外心肺复苏中的左心室卸载——一项多中心研究

Left-ventricular unloading in extracorporeal cardiopulmonary resuscitation due to acute myocardial infarction - A multicenter study.
PubMed 文献 · Resuscitation · 2023-03-21
一句话结论在急性心肌梗死所致难治性心脏骤停患者中,VA-ECMO联合Impella®(ECMELLA)与30天死亡风险降低相关(HR 0.53,95%CI 0.31-0.91,P=0.021)。

该多中心研究纳入2016年至2021年三个中心接受ECMELLA治疗的成人患者,按年龄、心电图节律、心脏骤停地点和SAVE评分进行倾向性评分匹配,与仅接受VA-ECMO的患者比较。主要终点30天死亡率:ECMELLA组风险降低(HR 0.53,95%CI 0.31-0.91,P=0.021);次要终点住院时间(IRR 1.71,95%CI 1.50-1.95,P<0.001)和ICU住院时间(IRR 1.81,95%CI 1.57-2.08,P<0.001)延长。ECMELLA组左心室射血分数至ICU出院时显著改善,低流量时间长和初始乳酸高的患者似乎受益更多。作者认为,对AMI所致难治性心脏骤停,VA-ECMO联合Impella®左心室卸载与患者结局改善相关。

要点

  • 在AMI所致难治性心脏骤停患者中,ECMELLA(VA-ECMO联合Impella®左心室卸载)与30天死亡风险降低相关(HR 0.53,95%CI 0.31-0.91,P=0.021)。
  • ECMELLA组住院时间(IRR 1.71,95%CI 1.50-1.95,P<0.001)和ICU住院时间(IRR 1.81,95%CI 1.57-2.08,P<0.001)较VA-ECMO组延长。
  • ECMELLA组左心室射血分数至ICU出院时显著改善。
  • 低流量时间较长和初始乳酸较高的患者似乎从额外左心室卸载中获益更多。
  • 研究为多中心倾向性评分匹配分析,ECMELLA与VA-ECMO的疗效差异仍需进一步研究。

适用人群与场景

  • 2016年至2021年在三个中心接受治疗的成人患者,因急性心肌梗死导致难治性心脏骤停,接受ECMELLA(VA-ECMO联合Impella®)或VA-ECMO治疗。

研究设计与关键结果

  • 研究类型:多中心研究,95例成人患者纳入,其中34对患者经倾向性评分匹配(基于年龄、心电图节律、心脏骤停地点和SAVE评分)。
  • 主要终点:ECMELLA治疗与30天死亡风险降低相关(HR 0.53,95%CI 0.31-0.91,P=0.021)。
  • 次要终点:ECMELLA组住院时间延长(IRR 1.71,95%CI 1.50-1.95,P<0.001),ICU住院时间延长(IRR 1.81,95%CI 1.57-2.08,P<0.001)。
  • ECMELLA组左心室射血分数至ICU出院时显著改善。
  • 亚组:低流量时间较长和初始乳酸较高的患者似乎从额外左心室卸载中获益更多。

证据类型、等级与局限

  • 证据类型:多中心研究,采用倾向性评分匹配、Cox比例风险模型和泊松回归模型分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在AMI所致难治性心脏骤停患者中,VA-ECMO联合Impella®进行左心室卸载与患者结局改善相关。
  • 对低流量时间较长和初始乳酸较高的患者,作者认为似乎可从额外左心室卸载中获益更多。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Guidelines advocate the use of extracorporeal cardio-pulmonary resuscitation with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in selected patients with cardiac arrest. Effects of concomitant left-ventricular (LV) unloading with Impella® (ECMELLA) remain unclear. This is the first study to investigate whether treatment with ECMELLA was associated with improved outcomes in patients with refractory cardiac arrest caused by acute myocardial infarction (AMI).

METHODS: This study was approved by the local ethical committee. Patients treated with ECMELLA at three centers between 2016 and 2021 were propensity score (PS)-matched to patients receiving VA-ECMO based on age, electrocardiogram rhythm, cardiac arrest location and Survival After Veno-Arterial ECMO (SAVE) score. Cox proportional-hazard and Poisson regression models were used to analyse 30-day mortality rate (primary outcome), hospital and intensive care unit (ICU) length of stay (LOS) (secondary outcomes). Sensitivity analyses on patient demographics and cardiac arrest parameters were performed.

RESULTS: 95 adult patients were included in this study, out of whom 34 pairs of patients were PS-matched. ECMELLA treatment was associated with decreased 30-day mortality risk (Hazard Ratio [HR] 0.53 [95% Confidence Interval (CI) 0.31-0.91], P = 0.021), prolonged hospital (Incidence Rate Ratio (IRR) 1.71 [95% CI 1.50-1.95], P < 0.001) and ICU LOS (IRR 1.81 [95% CI 1.57-2.08], P < 0.001). LV ejection fraction significantly improved until ICU discharge in the ECMELLA group. Especially patients with prolonged low-flow time and high initial lactate benefited from additional LV unloading.

CONCLUSIONS: LV unloading with Impella® concomitant to VA-ECMO therapy in patients with therapy-refractory cardiac arrest due to AMI was associated with improved patient outcomes.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Thevathasan T, Kenny MA, Krause FJ, et al. Left-ventricular unloading in extracorporeal cardiopulmonary resuscitation due to acute myocardial infarction - A multicenter study. Resuscitation. 2023. PMID: 36958632. doi:10.1016/j.resuscitation.2023.109775

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。